Dicot Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Dicot Pharma şirketinin toplam hissedar öz sermayesi SEK132.4M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK140.8M ve SEK8.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 130.40m
Eşitlik	SEK 132.40m
Toplam yükümlülükler	SEK 8.40m
Toplam varlıklar	SEK 140.80m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Dicot Pharma's (STO:DICOT) Cash Burn Situation

Nov 12

We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate

Apr 09

We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully

Dec 23

Recent updates

Here's Why We're Not Too Worried About Dicot Pharma's (STO:DICOT) Cash Burn Situation

Nov 12

We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate

Apr 09

We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully

Dec 23

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DICOT 'nin kısa vadeli varlıkları ( SEK140.8M ) kısa vadeli yükümlülüklerini ( SEK8.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: DICOT un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DICOT borçsuzdur.

Borcun Azaltılması: DICOT un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: DICOT şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: DICOT serbest nakit akışı her yıl % 26.3 1.9 yıl yetecek nakit akışına sahip olacaktır.

Dicot Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Dicot Pharma's (STO:DICOT) Cash Burn Situation

We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate

We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully

Dicot Ordinary Shares to Be Deleted from Other OTC

Recent updates

Dicot Pharma AB Appoints Håkan Wickholm as Chief Business Officer

Independent Chairman of the Board recently bought kr58k worth of stock

Here's Why We're Not Too Worried About Dicot Pharma's (STO:DICOT) Cash Burn Situation

Dicot Pharma Announces Initiation of Phase 2A Clinical Study

New major risk - Shareholder dilution

Independent Chairman of the Board recently bought kr51k worth of stock

Dicot Pharma AB (publ) Provides an Operational Update

Dicot Pharma AB to Report Q2, 2024 Results on Aug 23, 2024

Dicot Pharma Announces Clinical Trial Application for Phase 2A Trial

Dicot Pharma AB to Report Q3, 2024 Results on Aug 01, 2024

Dicot Pharma AB Completes a Pre-IND Meeting with FDA

Dicot Pharma AB Develops LIB-01 into A New Potency Drug with Improved Properties Compared to Currently Available Drugs

Dicot AB (publ) Announces Positive Safety and Improved Efficacy Results from Phase 1 Study

We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate

Dicot AB (publ) to Report Q1, 2024 Results on May 06, 2024

Dicot AB (publ) Announces Recruitment Completed in Dicot's Phase 1 Trial

New major risk - Financial position

Dicot AB (publ) to Report Fiscal Year 2023 Results on Feb 26, 2024

Dicot AB (publ) Presents Positive Results from the First Part of its Phase 1 Clinical Study

Dicot Applies for Patent Covering New Manufacturing Technology

We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully

Dicot AB (publ) Announces Partial Results from Phase 1 Trial to Be Presented Early Next Year

Director exercised options to buy kr169k worth of stock.

New minor risk - Share price stability

Dicot AB, Annual General Meeting, May 06, 2024

Dicot AB Initiates Repeated Dosing in Phase I Study

The Second Part of Dicot's Phase 1 Study Starts on October 20, 2023

Dicot AB to Report Q3, 2023 Results on Oct 31, 2023

Dicot AB Applies for International Patent Protection

Dicot AB Announces First Participants Dosed in Phase 1 Trial

Dicot AB Applies for US Patent

Dicot AB (publ) Announces Clinical Phase 1 Study Starts

Dicot AB Receives Approval to Start Phase 1 Clinical Trial

Dicot AB to Report Q2, 2023 Results on Aug 24, 2023

Director exercised options to buy kr194k worth of stock.

New major risk - Share price stability

Dicot AB (publ) Submits Application to Start Clinical Phase 1 Trial

Dicot to Seek Initiation of a Phase I Clinical Trial for the Drug Candidate Lib-01

Dicot's Study Drug Arrives in Sweden

Dicot AB Appoints Mats Silvander as New chief technical officer

Dicot AB Study Results Presented at European Society for Sexual Medicine

Dicot AB to Report Fiscal Year 2022 Results on Feb 27, 2023

No independent directors

Dicot AB Announces That It's Latest Study of the Mechanism of Action of LIB-01 Assumed to Be the Next Generation of Potency Drugs

Dicot AB Announces Successful First Regulatory Meeting for LIB-01

Dicot AB to Report Q3, 2022 Results on Nov 15, 2022

Dicot AB Reports Good Results from Preclinical Toxicology Studies

Dicot AB to Report Q2, 2022 Results on Aug 25, 2022

Dicot AB Moves Forward with New Patent Application

First quarter 2022 earnings released

No independent directors

Dicot AB Appoints Charlotta Gauffin as Chief Scientific Officer

Dicot AB Announces Board Changes

Dicot to Develop LIB-01 to an Oral Drug

Dicot AB Announces CEO Changes

Dicot Announces CFO Changes, Effective March 7, 2022

Dicot Announces That the Results of Dicot's Drug Candidate Will Be Presented At the European Society for Sexual Medicine

Dicot AB Announces Election of Eva Sjökvist Saers as the Chairman of Board, At the Extraordinary General Meeting Held on February 9, 2021

Dicot AB (publ) Broadens Testing of the Drug Candidate LIB-01

New 90-day low: kr0.94

Dicot Initiates Toxicology Studies Before Applying for Clinical Trials

New 90-day low: kr0.99

New 90-day low: kr1.06

Dicot Ordinary Shares to Be Deleted from Other OTC

New 90-day low: kr1.11

New 90-day low: kr1.33

Dicot AB Continues Studies with Pelvipharm to Generate Knowledge About Treatment Times, Doses and Libiguin's® Mechanism of Action

Dicot AB Announces That Sustainable Supply of Raw Material Important to Dicot

Dicot AB to Report Q2, 2020 Results on Aug 27, 2020

New 90-day high - kr2.45

Dicot AB to Report Q3, 2020 Results on Nov 23, 2020